The effects of atamestane and toremifene alone and in combination compared with letrozole on bone, serum lipids and the uterus in an ovariectomized rat model

Breast Cancer Research and Treatment

Volumn 103, Issue 3, 2007, Pages 293-302

  Goss, Paul E ^a   Qi, Shangle ^a   Hu, Haiqing ^a   Cheung, Angela M ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Atamestane; Bone; Letrozole; Lipid; Ovariectomized rat model; Toremifene; Uterine histology

Indexed keywords

ATAMESTANE; FLUTAMIDE; LETROZOLE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TOREMIFENE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE; BONE DENSITY; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; COMPRESSIVE STRENGTH; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOMETRIUM ATROPHY; FEMALE; HISTOLOGY; LIPID METABOLISM; LUMBAR VERTEBRA; MONOTHERAPY; MORPHOMETRICS; NONHUMAN; OVARIECTOMY; OVARY; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS; TRABECULAR BONE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UTERUS WEIGHT;

ANDROSTENEDIONE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LIPIDS; MODELS, CHEMICAL; NITRILES; ORGAN SIZE; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; TOREMIFENE; TRIAZOLES; UTERUS;

EID: 34250653326     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9381-y     Document Type: Article

References (44)

1. Kuhnz W, Hoyer GA, Backhus S, Jakobs U (1994) Metabolism of the steroidal aromatase inhibitor atamestane in rats, cynomolgus monkeys and humans. Isolation and identification of the major metabolites. Eur J Drug Metab Pharmacokinet 19:137-150
2. Shao TC, Marcelli M, Kong A, Cunningham GR (1995) Anti-androgen effects of the aromatase inhibitor, atamestane. J Androl 16:100-107
3. Hoffken K (1993) Experience with aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev Suppl B 19:37-44
4. Kelloff GJ, Lubet RA, Lieberman R, Eisenhauer K, Steele VE, Crowell JA, Hawk ET, Boone CW, Sigman CC (1998) Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 7:65-78
5. Milla-Santos A, Milla L, Rallo L, Solano V (2001) Phase III randomized trial of toremifene vs. tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Res Treat 65:119-124
6. Pagani O, Gelber S, Price K, Zahrieh D, Gelber R, Simoncini E, Castiglione-Gertsch M, Coates AS, Goldhirsch A (2004) International Breast Cancer Study Group: toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 15:1749-1759
7. Ellmen J, Hakulinen P, Partanen A, Hayes DF (2003) Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res Treat 82:103-111
8. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802
9. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price N, Goldhirsch A (2006) Breast International Group (BIG) 1-98 Collaborative Group: a comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005. Erratum in: N Engl J Med 354:2200, 2006
10. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T (2003) The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810
11. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group: Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7:633-643, 2006
12. Buzdar AU (2006) Anastrozole for breast cancer: recent advances and ongoing challenges. Expert Rev Anticancer Ther 6:839-848
13. Di Salle E, Zaccheo T, Ornati G (1990) Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem 36:203-206
14. Jordan VC, Phelps E, Lindgren JU (1987) Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10:31-35
15. Yamazaki I, Yamaguchi H (1989) Characteristics of an ovariectomized osteopenic rat model. J Bone Miner Res 4:13-22
16. Wronski TJ, Yen CF (1991) The ovariectomized rat as an animal model for postmenopausal bone loss. Cells Mater 1(Suppl):69-74
17. Kalu DN (1991) The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15:175-191
18. Lundeen SG, Carver JM, Mckean ML, Winneker RC (1997) Characterization of the ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels. Endocrinology 138:1552-1558
19. Vanin CM, MacLusky NJ, Grynpas MD, Casper RF (1995) The effect of three hormone replacement regimens on bone density in the aged ovariectomized rat. Fertil Steril 63:643-651
20. Chachra D, Vanin CM, MacLusky NJ, Casper RF, Grynpas MD (1995) The effect of different hormone replacement therapy regimens on the mechanical properties of rat vertebrae. Calcif Tissue Int 56:130-134
21. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization nomenclature, symbols and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
22. Quarles LD, Lobaugh B (1989) Equivalency of various methods for estimating osteoid seam width. J Bone Miner Res 4:671-677
23. Huffer WE, Lepoff RB (1992) An indirect method of measuring widths suitable for automated bone histomorphometry. J Bone Miner Res 7:1417-1427
24. Huffer WE, Ruegg P, Zhu JM, Lepoff RB (1994) Semiautomated methods for cancellous bone histomorphometry using a general-purpose video image analysis system. J Microsc 173:53-66
25. Steiniche T (1995) Bone histomorphometry in the pathophysiological evaluation of primary and secondary osteoporosis and various treatment modalities. APMIS Suppl 51:1-44
26. Karlsson S, Mantyla E, Hirsimaki Y, Niemi S, Nieminen L, Nieminen K, Kangas L (1999) The effect of toremifene on bone and uterine histology and on bone resorption in ovariectomised rats. Pharmacol Toxicol 84:72-80
27. Nephew KP, Osborne E, Lubet RA, Grubbs CJ, Khan SA (2000) Effects of oral administration of tamoxifen, toremifene, dehydroepiandrosterone, and vorozole on uterine histomorphology in the rat. Proc Soc Exp Biol Med 223:288-294
28. Gutman M, Couillard S, Roy J, Labrie F, Candas B, Labrie C (2002) Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. Int J Cancer 99:273-278
29. Kusama M, Miyauchi K, Aoyama H, Sano M, Kimura M, Mitsuyama S, Komaki K, Doihara H (2004a) Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. Breast Cancer Res Treat 88:1-8
30. Kusama M, Kaise H, Nakayama S, Ota D, Misaka T, Aoki T (2004b) Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations. Breast Cancer Res Treat 88:9-16
31. Erkkola R, Mattila L, Powles T, Heikkinen J, Toivola B, Korhonen P, Mustonen M (2005) Bone mineral density and lipid changes during 5 years of follow-up in a study of prevention of breast cancer with toremifene in healthy, high-risk pre- and post-menopausal women. Breast Cancer Res Treat 93:277-287
32. Windler EE, Kovanen PT, Chao YS, Brown MS, Havel RJ, Goldstein JL (1980) The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J Biol Chem 255:10464-10471
33. Chao YS, Windler EE, Chen GC, Havel RJ (1979) Hepatic catabolism of rat and human lipoproteins in rats-treated with 17α-ethynyl estradiol. J Biol Chem 254:11360-11366
34. Martel C, Picard S, Richard V, Belanger A, Labrie C, Labrie F (2000) Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J. Steroid Biochem Mol Biol 74:45-56
35. Goss PE, Qi S, Josse RG, Pritzker KPH, Mendes M, Hu H, Waldman SD, Grynpas MD (2004a) The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 34:384-392
36. Goss PE, Qi S, Cheung AM, Hu H, Mendes M, Pritzker KPH (2004b) Effects of the steroidal aromatase inhibitor exemestane and the non-steroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res 10:5717-5723
37. Goss PE, Qi S, Cheung AM, Hu H, Mendes M, Pritzker KPH (2004c) The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats. J Steroid Biochem Mol Biol 92:79-87
38. Ederveen AG, Kloosterboer HJ (2001) Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. Bone Miner Res 16:1651-1657
39. Habenicht UF, el Etreby MF (1989) Selective inhibition of androstenedione-induced prostate growth in intact beagle dogs by a combined treatment with the antiandrogen cyproterone acetate and the aromatase inhibitor 1-methyl-androsta-1,4-diene-3,17-dione (1-methyl-ADD). Prostate 4:309-322
40. Zaccheo T, Giudici D, Ornati G, Panzeri A, di Salle E (1991) Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours. Eur J Cancer 27:1145-1150
41. Chandrasekhar Y (1991) Effects of hydroxyflutamide on female reproductive function. Adv Contracept Deliv Syst 7:157-166
42. Kunimatsu T, Yamada T, Ose K, Sunami O, Kamita Y, Okuno Y, Seki T, Nakatsuka I (2002) Lack of (anti-) androgenic or estrogenic effects of three pyrethroids (esfenvalerate, fenvalerate, and permethrin) in the Hershberger and uterotrophic assays. Regul Toxicol Pharmacol 35:227-237
43. de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ (2003) Receptor profiling and endocrine interactions of tibolone. Steroids 68:21-30
44. Nantermet PV, Masarachia P, Gentile MA, Pennypacker B, Xu J, Holder D, Gerhold D, Towler D, Schmidt A, Kimmel DB, Freedman LP, Harada S, Ray WJ (2005) Androgenic induction of growth and differentiation in the rodent uterus involves the modulation of estrogen-regulated genetic pathways. Endocrinology 146:564-578